EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tesaro's Enterprise Value is $4,127.9 Mil.
Tesaro's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 was $-588.5 Mil. Therefore, Tesaro's EV-to-EBIT for today is -7.01.
The historical rank and industry rank for Tesaro's EV-to-EBIT or its related term are showing as below:
TSRO's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 8.41 * Ranked among companies with meaningful EV-to-EBIT only.
The historical data trend for Tesaro's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tesaro's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tesaro's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tesaro's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Tesaro's EV-to-EBIT falls into.
Tesaro's current Enterprise Value is $4,127.9 Mil.
Tesaro's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-588.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tesaro (NAS:TSRO) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Tesaro's Enterprise Value for the quarter that ended in Sep. 2018 was $2,313.7 Mil.
Tesaro's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-588.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tesaro EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Tesaro's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSRO has been successfully added to your 